D46/NS2/N/ΔM2-2-HindIII

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for D46/NS2/N/ΔM2-2-HindIII, covering 2019-06-14 to 2019-06-14. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age [Phase 1]

See pricing